FDA approves Merilog (insulin-aspart-szjj) the first rapid-acting insulin biosimilar product for treatment of diabetes – Sanofi
The FDA has approved Merilog (insulin-aspart-szjj) as biosimilar to NovoLog (insulin aspart) from Sanofi for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus…. read more.
